Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15)

Pfizer

Status and phase

Enrolling

Phase 4

Conditions

Multiple Myeloma

Treatments

Drug: Elranatamab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06057402

2023-505200-33-00 (Registry Identifier)

C1071015

Details and patient eligibility

About

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Full description

This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.

Enrollment

72 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must agree to follow the reproductive criteria as outlined in the protocol
Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion criteria

Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.